T-cell engager (TCE)-based immunotherapy requires further development in solid tumors due to limited T cell penetration, immunosuppressive tumor microenvironment and toxicity. The authors here develop a glypican-3 targeting mRNA TCE (MTS105) which manifests superior T cell activation and tumor regression hepatocellular carcinoma mice model comparing to conventional TCE, and safety with cynomolgus monkey studies.
- Yan Huang
- Shaoli Liu
- Wei Xu